InNexus Biotechnology (InNexus Biotechnology) Net Income From Continuing Operations : $-4.15 Mil (TTM As of Mar. 2011)

View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. InNexus Biotechnology's net income from continuing operations for the three months ended in Mar. 2011 was $-0.57 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2011 was $-4.15 Mil.

InNexus Biotechnology Net Income From Continuing Operations Historical Data

The historical data trend for InNexus Biotechnology's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Net Income From Continuing Operations Chart

InNexus Biotechnology Annual Data

Trend

Jun01

Jun02

Jun03

Jun04

Jun05

Jun06

Jun07

Jun08

Jun09

Jun10

Net Income From Continuing Operations

Get a 7-Day Free Trial

-2.63

-4.86

-5.79

-7.12

-6.45

InNexus Biotechnology Quarterly Data
	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11
Net Income From Continuing Operations	Get a 7-Day Free Trial															-1.59	-1.84	-0.94	-0.79	-0.57

InNexus Biotechnology Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.15 Mil.

InNexus Biotechnology (InNexus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7

Website

http://www.ixsbio.com

InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines